 Brent Palmer
Concepts (454)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 40 | 2026 | 3154 | 3.770 |
Why?
| | CD4-Positive T-Lymphocytes | 34 | 2021 | 1129 | 3.160 |
Why?
| | Gastrointestinal Microbiome | 11 | 2026 | 771 | 2.540 |
Why?
| | Homosexuality, Male | 6 | 2026 | 222 | 2.270 |
Why?
| | Microbiota | 8 | 2024 | 781 | 1.400 |
Why?
| | HIV-1 | 17 | 2018 | 896 | 1.350 |
Why?
| | Sexual and Gender Minorities | 4 | 2022 | 251 | 1.250 |
Why?
| | HIV | 5 | 2019 | 250 | 1.230 |
Why?
| | Programmed Cell Death 1 Receptor | 11 | 2019 | 264 | 1.090 |
Why?
| | Inflammation | 10 | 2026 | 2878 | 0.980 |
Why?
| | Dysbiosis | 3 | 2021 | 187 | 0.920 |
Why?
| | Virus Replication | 5 | 2010 | 529 | 0.860 |
Why?
| | Epitopes, T-Lymphocyte | 6 | 2010 | 175 | 0.850 |
Why?
| | Lymphocyte Activation | 16 | 2018 | 1126 | 0.840 |
Why?
| | Receptors, CCR5 | 4 | 2021 | 60 | 0.840 |
Why?
| | Feces | 5 | 2025 | 513 | 0.800 |
Why?
| | CD8-Positive T-Lymphocytes | 16 | 2021 | 917 | 0.780 |
Why?
| | Berylliosis | 6 | 2013 | 202 | 0.700 |
Why?
| | Antigens, CD | 9 | 2020 | 555 | 0.700 |
Why?
| | Gastrointestinal Tract | 2 | 2014 | 208 | 0.680 |
Why?
| | Viral Load | 9 | 2020 | 526 | 0.660 |
Why?
| | Macrophages, Alveolar | 3 | 2020 | 368 | 0.660 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2016 | 278 | 0.630 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 6 | 0.630 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 474 | 0.630 |
Why?
| | Up-Regulation | 9 | 2019 | 851 | 0.620 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.590 |
Why?
| | Varicellovirus | 4 | 2022 | 17 | 0.580 |
Why?
| | Apoptosis Regulatory Proteins | 3 | 2008 | 186 | 0.560 |
Why?
| | Leukocytes, Mononuclear | 7 | 2022 | 573 | 0.560 |
Why?
| | T-Lymphocyte Subsets | 10 | 2016 | 415 | 0.530 |
Why?
| | CD57 Antigens | 3 | 2007 | 18 | 0.510 |
Why?
| | Beryllium | 6 | 2009 | 161 | 0.490 |
Why?
| | Cytokines | 12 | 2021 | 2061 | 0.480 |
Why?
| | Interferon-gamma | 13 | 2013 | 784 | 0.480 |
Why?
| | B7-H1 Antigen | 6 | 2019 | 241 | 0.470 |
Why?
| | Anti-HIV Agents | 5 | 2016 | 888 | 0.470 |
Why?
| | Humans | 88 | 2026 | 144759 | 0.470 |
Why?
| | Lung | 16 | 2022 | 4109 | 0.450 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 103 | 0.450 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 676 | 0.440 |
Why?
| | Bacteria | 4 | 2022 | 889 | 0.440 |
Why?
| | Viremia | 5 | 2018 | 158 | 0.430 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2022 | 1217 | 0.430 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 389 | 0.420 |
Why?
| | Biota | 1 | 2013 | 35 | 0.400 |
Why?
| | B-Lymphocytes | 7 | 2022 | 876 | 0.380 |
Why?
| | Immunophenotyping | 9 | 2020 | 322 | 0.380 |
Why?
| | Bronchoalveolar Lavage Fluid | 9 | 2020 | 636 | 0.380 |
Why?
| | Prevotella | 2 | 2025 | 26 | 0.370 |
Why?
| | Herpesviridae Infections | 4 | 2019 | 150 | 0.370 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2009 | 23 | 0.370 |
Why?
| | T-Lymphocytes | 9 | 2018 | 1982 | 0.360 |
Why?
| | Adult | 32 | 2026 | 40449 | 0.360 |
Why?
| | Anti-Retroviral Agents | 4 | 2024 | 250 | 0.350 |
Why?
| | Down-Regulation | 2 | 2016 | 627 | 0.340 |
Why?
| | Herpes Zoster | 4 | 2022 | 315 | 0.330 |
Why?
| | Interleukin-2 | 5 | 2013 | 437 | 0.330 |
Why?
| | Herpesvirus 3, Human | 4 | 2022 | 336 | 0.320 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 558 | 0.320 |
Why?
| | Male | 37 | 2026 | 72315 | 0.310 |
Why?
| | Gene Products, gag | 3 | 2016 | 38 | 0.300 |
Why?
| | Receptors, OX40 | 1 | 2009 | 15 | 0.300 |
Why?
| | Interleukin-10 | 4 | 2022 | 309 | 0.290 |
Why?
| | Middle Aged | 27 | 2026 | 35875 | 0.280 |
Why?
| | Antibodies, Viral | 4 | 2022 | 672 | 0.270 |
Why?
| | Virus Activation | 3 | 2019 | 95 | 0.270 |
Why?
| | Immune System | 2 | 2019 | 179 | 0.270 |
Why?
| | Chronic Disease | 9 | 2014 | 1813 | 0.270 |
Why?
| | Membrane Proteins | 3 | 2013 | 1166 | 0.270 |
Why?
| | Vitiligo | 2 | 2019 | 42 | 0.260 |
Why?
| | Meningitis, Cryptococcal | 2 | 2020 | 34 | 0.260 |
Why?
| | Cerebrospinal Fluid | 2 | 2020 | 88 | 0.260 |
Why?
| | Dendritic Cells | 8 | 2019 | 499 | 0.260 |
Why?
| | Interleukin-1 | 3 | 2019 | 961 | 0.260 |
Why?
| | Vaccination | 3 | 2021 | 1423 | 0.250 |
Why?
| | Immunologic Factors | 2 | 2022 | 255 | 0.250 |
Why?
| | Sexual Behavior | 3 | 2020 | 491 | 0.250 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2010 | 668 | 0.250 |
Why?
| | Female | 34 | 2026 | 78271 | 0.240 |
Why?
| | Mice | 18 | 2024 | 18339 | 0.240 |
Why?
| | Cohort Studies | 8 | 2019 | 5960 | 0.240 |
Why?
| | Animals | 26 | 2024 | 38058 | 0.230 |
Why?
| | Gene Expression | 1 | 2010 | 1490 | 0.230 |
Why?
| | Host-Pathogen Interactions | 3 | 2024 | 371 | 0.220 |
Why?
| | DNA, Bacterial | 2 | 2019 | 342 | 0.220 |
Why?
| | Immunity, Innate | 3 | 2019 | 846 | 0.220 |
Why?
| | Interleukin-12 | 2 | 2022 | 117 | 0.210 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.200 |
Why?
| | Cell Proliferation | 8 | 2010 | 2496 | 0.190 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 463 | 0.190 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2022 | 40 | 0.190 |
Why?
| | Interleukin-6 | 3 | 2022 | 780 | 0.190 |
Why?
| | Smokers | 2 | 2020 | 137 | 0.190 |
Why?
| | Disease Models, Animal | 7 | 2024 | 4557 | 0.190 |
Why?
| | Flow Cytometry | 9 | 2015 | 1173 | 0.180 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 138 | 0.180 |
Why?
| | Peripheral Tolerance | 1 | 2022 | 14 | 0.180 |
Why?
| | Young Adult | 9 | 2020 | 14105 | 0.180 |
Why?
| | HIV Core Protein p24 | 5 | 2010 | 32 | 0.180 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 161 | 0.180 |
Why?
| | Monocytes | 4 | 2019 | 538 | 0.170 |
Why?
| | Lymph Nodes | 3 | 2019 | 502 | 0.170 |
Why?
| | Exanthema | 1 | 2022 | 84 | 0.170 |
Why?
| | Chickenpox | 1 | 2022 | 81 | 0.170 |
Why?
| | Killer Cells, Natural | 3 | 2014 | 467 | 0.170 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 264 | 0.170 |
Why?
| | Polysaccharides, Bacterial | 2 | 2022 | 67 | 0.160 |
Why?
| | Immunologic Memory | 6 | 2014 | 366 | 0.160 |
Why?
| | Immunity, Humoral | 1 | 2021 | 120 | 0.160 |
Why?
| | Macaca mulatta | 5 | 2022 | 191 | 0.160 |
Why?
| | Lymphocyte Depletion | 3 | 2019 | 132 | 0.160 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 4 | 2019 | 29 | 0.160 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 108 | 0.160 |
Why?
| | Lung Diseases | 3 | 2017 | 787 | 0.160 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.160 |
Why?
| | Pneumocystis | 2 | 1996 | 8 | 0.160 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 72 | 0.160 |
Why?
| | Cell Compartmentation | 1 | 2020 | 54 | 0.160 |
Why?
| | Haplotypes | 2 | 2019 | 490 | 0.150 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 169 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2021 | 155 | 0.150 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 194 | 0.150 |
Why?
| | HLA-DR Antigens | 4 | 2016 | 220 | 0.150 |
Why?
| | Fetal Blood | 2 | 2014 | 342 | 0.150 |
Why?
| | Cells, Cultured | 9 | 2016 | 4154 | 0.150 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 173 | 0.150 |
Why?
| | Audiovisual Aids | 1 | 2019 | 11 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 16 | 0.150 |
Why?
| | CD4 Lymphocyte Count | 4 | 2013 | 277 | 0.150 |
Why?
| | Genes, MHC Class II | 1 | 2019 | 76 | 0.140 |
Why?
| | Disease | 1 | 2019 | 98 | 0.140 |
Why?
| | Diet | 1 | 2026 | 1273 | 0.140 |
Why?
| | Virus Latency | 1 | 2019 | 90 | 0.140 |
Why?
| | Fluorescent Antibody Technique | 4 | 2015 | 370 | 0.140 |
Why?
| | Monkey Diseases | 1 | 2018 | 25 | 0.140 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 122 | 0.140 |
Why?
| | Emtricitabine | 2 | 2016 | 205 | 0.140 |
Why?
| | Green Fluorescent Proteins | 2 | 2018 | 405 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 442 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2015 | 223 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2023 | 592 | 0.130 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2018 | 94 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2018 | 197 | 0.130 |
Why?
| | Pneumonia, Pneumocystis | 2 | 1996 | 34 | 0.130 |
Why?
| | Tenofovir | 2 | 2016 | 295 | 0.130 |
Why?
| | Open Reading Frames | 1 | 2018 | 132 | 0.130 |
Why?
| | CTLA-4 Antigen | 2 | 2019 | 104 | 0.130 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1047 | 0.130 |
Why?
| | Colon | 1 | 2020 | 304 | 0.130 |
Why?
| | Case-Control Studies | 7 | 2020 | 3604 | 0.120 |
Why?
| | Vaccines, DNA | 1 | 2016 | 31 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2020 | 291 | 0.120 |
Why?
| | Melanoma | 3 | 2008 | 761 | 0.120 |
Why?
| | Aged | 11 | 2019 | 25913 | 0.120 |
Why?
| | Genitalia | 1 | 2016 | 34 | 0.120 |
Why?
| | Skin | 2 | 2019 | 755 | 0.120 |
Why?
| | Biopsy | 1 | 2020 | 1075 | 0.120 |
Why?
| | Immunization, Secondary | 1 | 2016 | 91 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 154 | 0.120 |
Why?
| | Withholding Treatment | 1 | 2016 | 80 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2016 | 379 | 0.120 |
Why?
| | Mice, Knockout | 5 | 2021 | 3121 | 0.120 |
Why?
| | Hepatitis C | 2 | 2009 | 254 | 0.120 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2016 | 364 | 0.110 |
Why?
| | Retroviridae Infections | 1 | 2015 | 47 | 0.110 |
Why?
| | Mouth | 1 | 2015 | 88 | 0.110 |
Why?
| | Cytomegalovirus Infections | 2 | 2015 | 206 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2016 | 202 | 0.110 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 415 | 0.110 |
Why?
| | Zimbabwe | 2 | 2026 | 76 | 0.110 |
Why?
| | Rectum | 1 | 2016 | 180 | 0.110 |
Why?
| | Immune Evasion | 1 | 2015 | 64 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2018 | 509 | 0.110 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 20 | 0.110 |
Why?
| | Immunization | 2 | 2008 | 374 | 0.110 |
Why?
| | Organophosphonates | 1 | 2015 | 97 | 0.110 |
Why?
| | Survivors | 2 | 2016 | 520 | 0.110 |
Why?
| | Receptors, Interleukin-1 | 1 | 2015 | 213 | 0.100 |
Why?
| | Immunotherapy | 1 | 2019 | 653 | 0.100 |
Why?
| | Software | 1 | 2019 | 690 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 209 | 0.100 |
Why?
| | Macrophages | 4 | 2015 | 1511 | 0.100 |
Why?
| | Deoxycytidine | 1 | 2015 | 221 | 0.100 |
Why?
| | Adolescent | 5 | 2020 | 22428 | 0.100 |
Why?
| | Mortality | 1 | 2016 | 375 | 0.100 |
Why?
| | Tropheryma | 1 | 2013 | 6 | 0.100 |
Why?
| | Whipple Disease | 1 | 2013 | 7 | 0.100 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 94 | 0.100 |
Why?
| | Smoking | 1 | 2020 | 1472 | 0.100 |
Why?
| | Leukocyte Common Antigens | 3 | 2011 | 88 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2012 | 1253 | 0.100 |
Why?
| | Biomarkers | 6 | 2019 | 4271 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 27 | 0.100 |
Why?
| | 4-1BB Ligand | 2 | 2009 | 7 | 0.090 |
Why?
| | Adenine | 1 | 2015 | 339 | 0.090 |
Why?
| | Hematopoiesis | 2 | 2011 | 194 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 248 | 0.090 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2015 | 246 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 286 | 0.090 |
Why?
| | Cytomegalovirus | 3 | 2015 | 168 | 0.090 |
Why?
| | Receptors, CXCR4 | 2 | 2010 | 91 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2013 | 824 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 920 | 0.080 |
Why?
| | Th1 Cells | 2 | 2013 | 139 | 0.080 |
Why?
| | RNA, Viral | 3 | 2004 | 688 | 0.080 |
Why?
| | Prognosis | 2 | 2017 | 4282 | 0.080 |
Why?
| | Cell Line | 5 | 2018 | 2882 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 721 | 0.080 |
Why?
| | CCR5 Receptor Antagonists | 1 | 2010 | 6 | 0.080 |
Why?
| | Metagenome | 1 | 2011 | 149 | 0.080 |
Why?
| | Lymphocyte Count | 4 | 2017 | 164 | 0.080 |
Why?
| | Ecology | 1 | 2011 | 121 | 0.080 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2930 | 0.080 |
Why?
| | Ligands | 2 | 2014 | 673 | 0.080 |
Why?
| | Forkhead Transcription Factors | 2 | 2010 | 202 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2363 | 0.080 |
Why?
| | Hydroxamic Acids | 1 | 2010 | 94 | 0.080 |
Why?
| | Skin Neoplasms | 2 | 2007 | 847 | 0.080 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2007 | 131 | 0.080 |
Why?
| | OX40 Ligand | 1 | 2009 | 10 | 0.070 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 28 | 0.070 |
Why?
| | Cell Lineage | 1 | 2011 | 376 | 0.070 |
Why?
| | Vagina | 1 | 2011 | 201 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 81 | 0.070 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1519 | 0.070 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 220 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1180 | 0.070 |
Why?
| | Risk Factors | 2 | 2020 | 10779 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2009 | 148 | 0.070 |
Why?
| | Cell Division | 2 | 2013 | 766 | 0.070 |
Why?
| | Convalescence | 1 | 2007 | 19 | 0.070 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 37 | 0.070 |
Why?
| | Genes, rev | 1 | 2007 | 2 | 0.070 |
Why?
| | Genes, tat | 1 | 2007 | 3 | 0.070 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2608 | 0.060 |
Why?
| | Arthritis, Experimental | 1 | 2009 | 141 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 523 | 0.060 |
Why?
| | Bronchoalveolar Lavage | 1 | 2007 | 89 | 0.060 |
Why?
| | Tumor Escape | 1 | 2007 | 49 | 0.060 |
Why?
| | Cystatins | 1 | 2006 | 7 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 100 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2009 | 1306 | 0.060 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2007 | 93 | 0.060 |
Why?
| | RNA, Catalytic | 1 | 2007 | 189 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2021 | 395 | 0.060 |
Why?
| | Ecosystem | 1 | 2011 | 589 | 0.060 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 31 | 0.060 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2005 | 45 | 0.060 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 47 | 0.060 |
Why?
| | Prospective Studies | 4 | 2016 | 7990 | 0.060 |
Why?
| | Hepacivirus | 1 | 2007 | 243 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 675 | 0.060 |
Why?
| | Hepatitis C, Chronic | 1 | 2007 | 152 | 0.060 |
Why?
| | Signal Transduction | 4 | 2021 | 5226 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2007 | 635 | 0.050 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2019 | 14 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 341 | 0.050 |
Why?
| | Antigens, CD34 | 3 | 2011 | 88 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.050 |
Why?
| | United States | 1 | 2021 | 15966 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 863 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1499 | 0.050 |
Why?
| | Neoplasms | 1 | 2019 | 2875 | 0.050 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5992 | 0.050 |
Why?
| | Urban Population | 1 | 2026 | 491 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 35 | 0.050 |
Why?
| | Immunoglobulin D | 1 | 2022 | 29 | 0.050 |
Why?
| | CD4 Antigens | 3 | 2007 | 139 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2006 | 395 | 0.050 |
Why?
| | Bacteroides fragilis | 1 | 2022 | 14 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2002 | 62 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 100 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2015 | 2050 | 0.050 |
Why?
| | Hypersensitivity | 1 | 2005 | 252 | 0.040 |
Why?
| | Allergens | 1 | 2005 | 384 | 0.040 |
Why?
| | Cell Count | 2 | 2016 | 320 | 0.040 |
Why?
| | Mice, SCID | 2 | 2007 | 369 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2003 | 331 | 0.040 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 235 | 0.040 |
Why?
| | CD28 Antigens | 2 | 2013 | 58 | 0.040 |
Why?
| | Rural Population | 1 | 2026 | 650 | 0.040 |
Why?
| | Interferons | 1 | 2022 | 188 | 0.040 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2947 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 138 | 0.040 |
Why?
| | Transforming Growth Factor beta | 3 | 2008 | 479 | 0.040 |
Why?
| | Species Specificity | 2 | 2016 | 574 | 0.040 |
Why?
| | Immunity | 1 | 2021 | 139 | 0.040 |
Why?
| | Phenotype | 3 | 2019 | 3162 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 40 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2182 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1169 | 0.040 |
Why?
| | Bacteroides | 1 | 2019 | 20 | 0.040 |
Why?
| | B7-2 Antigen | 2 | 2013 | 27 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1716 | 0.040 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 27 | 0.040 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 1999 | 23 | 0.040 |
Why?
| | Ganglia | 1 | 2019 | 18 | 0.040 |
Why?
| | HLA-DQ beta-Chains | 1 | 2019 | 57 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2019 | 2832 | 0.040 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 89 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 803 | 0.040 |
Why?
| | Spondylarthritis | 1 | 2019 | 50 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 80 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 122 | 0.040 |
Why?
| | Survival Rate | 2 | 2017 | 2089 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2019 | 246 | 0.030 |
Why?
| | Coinfection | 1 | 2020 | 141 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8265 | 0.030 |
Why?
| | Genetic Loci | 1 | 2019 | 261 | 0.030 |
Why?
| | Protein Transport | 1 | 2019 | 441 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 160 | 0.030 |
Why?
| | Virus Diseases | 1 | 2019 | 216 | 0.030 |
Why?
| | Cell Communication | 1 | 2018 | 324 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 43 | 0.030 |
Why?
| | Sheep | 1 | 1999 | 880 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 479 | 0.030 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 496 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 323 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 109 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 618 | 0.030 |
Why?
| | Virulence | 1 | 1996 | 278 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 851 | 0.030 |
Why?
| | Neuroglia | 1 | 2016 | 172 | 0.030 |
Why?
| | Retroviridae | 1 | 2015 | 101 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 84 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 358 | 0.030 |
Why?
| | Viral Proteins | 1 | 2018 | 355 | 0.030 |
Why?
| | HIV Antigens | 1 | 2015 | 17 | 0.030 |
Why?
| | Immobilized Proteins | 1 | 2015 | 10 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 661 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 76 | 0.030 |
Why?
| | Blood Cells | 1 | 2014 | 37 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 682 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6429 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1501 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 365 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 83 | 0.030 |
Why?
| | Extracellular Space | 1 | 2015 | 120 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 192 | 0.030 |
Why?
| | Safety | 1 | 2016 | 356 | 0.030 |
Why?
| | Endotoxemia | 1 | 2015 | 87 | 0.030 |
Why?
| | Endostatins | 1 | 2013 | 10 | 0.030 |
Why?
| | Activins | 1 | 2013 | 29 | 0.030 |
Why?
| | Integrin alphaVbeta3 | 1 | 2013 | 20 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 266 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1833 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 401 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2013 | 54 | 0.020 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 109 | 0.020 |
Why?
| | B7-1 Antigen | 1 | 2013 | 55 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1137 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2015 | 766 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.020 |
Why?
| | DNA, Viral | 1 | 2015 | 358 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.020 |
Why?
| | Lymphokines | 1 | 2013 | 130 | 0.020 |
Why?
| | Muromegalovirus | 1 | 2013 | 23 | 0.020 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 108 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1135 | 0.020 |
Why?
| | Models, Immunological | 1 | 2013 | 100 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 197 | 0.020 |
Why?
| | Prednisone | 1 | 2014 | 221 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2017 | 732 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2013 | 271 | 0.020 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 178 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2013 | 96 | 0.020 |
Why?
| | Interleukin-15 | 1 | 2013 | 97 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 862 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1370 | 0.020 |
Why?
| | Peritoneum | 1 | 2011 | 45 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2925 | 0.020 |
Why?
| | Fibroblasts | 1 | 2016 | 1034 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 557 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2015 | 893 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2011 | 80 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2010 | 43 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2011 | 160 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2011 | 127 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 7190 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2017 | 1339 | 0.020 |
Why?
| | Valproic Acid | 1 | 2010 | 47 | 0.020 |
Why?
| | Glioblastoma | 1 | 2013 | 353 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1125 | 0.020 |
Why?
| | Antibody Formation | 1 | 2011 | 294 | 0.020 |
Why?
| | CD3 Complex | 1 | 2010 | 111 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2010 | 336 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2014 | 535 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 348 | 0.020 |
Why?
| | Radiation Chimera | 1 | 2009 | 27 | 0.020 |
Why?
| | Radiation Injuries, Experimental | 1 | 2009 | 20 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 846 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2009 | 187 | 0.020 |
Why?
| | Glucocorticoid-Induced TNFR-Related Protein | 1 | 2008 | 5 | 0.020 |
Why?
| | Bone Resorption | 1 | 2009 | 80 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2145 | 0.020 |
Why?
| | Liver | 2 | 2007 | 1887 | 0.020 |
Why?
| | Remission, Spontaneous | 1 | 2007 | 40 | 0.020 |
Why?
| | Research | 1 | 2011 | 431 | 0.020 |
Why?
| | Alleles | 2 | 2003 | 879 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 294 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 4089 | 0.020 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.020 |
Why?
| | Toll-Like Receptor 2 | 1 | 2008 | 126 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2194 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2007 | 111 | 0.020 |
Why?
| | Transplantation Chimera | 1 | 2007 | 56 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 245 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 177 | 0.020 |
Why?
| | Precision Medicine | 1 | 2011 | 457 | 0.020 |
Why?
| | Blood | 1 | 2007 | 109 | 0.020 |
Why?
| | Cystatin C | 1 | 2006 | 65 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2006 | 72 | 0.020 |
Why?
| | Fibrosis | 1 | 2009 | 548 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2007 | 206 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2006 | 193 | 0.010 |
Why?
| | Toll-Like Receptor 4 | 1 | 2008 | 276 | 0.010 |
Why?
| | Gene Silencing | 1 | 2007 | 205 | 0.010 |
Why?
| | Bacillus subtilis | 1 | 2006 | 69 | 0.010 |
Why?
| | Thymus Gland | 1 | 2007 | 311 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6048 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2007 | 337 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 381 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2007 | 272 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 7173 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2430 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10034 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2933 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11787 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1462 | 0.010 |
Why?
| | Aging | 1 | 2014 | 1966 | 0.010 |
Why?
| | Clone Cells | 1 | 2003 | 266 | 0.010 |
Why?
| | HLA-DRB1 Chains | 1 | 2003 | 109 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2003 | 245 | 0.010 |
Why?
| | CD40 Antigens | 1 | 2002 | 90 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1980 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 74 | 0.010 |
Why?
| | Germ Cells | 1 | 1999 | 66 | 0.010 |
Why?
| | Child | 1 | 2019 | 22633 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1999 | 276 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1999 | 366 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1999 | 396 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1999 | 540 | 0.010 |
Why?
| | Disease Progression | 1 | 2005 | 2847 | 0.010 |
Why?
| | Opportunistic Infections | 1 | 1996 | 45 | 0.010 |
Why?
| | Protein Binding | 1 | 2003 | 2273 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1999 | 612 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1054 | 0.010 |
Why?
| | Base Sequence | 1 | 1999 | 2190 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 2155 | 0.010 |
Why?
| | Genetic Variation | 1 | 1999 | 983 | 0.010 |
Why?
|
|
Palmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|